Insight about the characteristics and surgical resectability of adult pilocytic astrocytoma: tertiary center experience

Baha’eddin A Muhsen*,1,2, Abdelmajid I Aljariri3, Maher Elayyan1 & Hawazen Hirbawi4 & Mahmoud A Masri5

1Division of Neurosurgery, Department of Surgery, King Hussein Cancer Center, Amman, 11941, Jordan
2Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
3Department of Surgery, Albashir Hospital, Amman, 11151, Jordan
4Department of Medicine, Istishari Hospital, Amman, 11194, Jordan
5Department of Surgery, King Hussein Cancer Center, Amman, 11941, Jordan

*Author for correspondence: bmuhsen08@gmail.com

Aim: Adult pilocytic astrocytoma is a rare tumor. We aim to contribute to understanding its clinical course and prognosis. Patients & methods: We searched our database for patients older than 18 years with pathology-proven pilocytic astrocytoma. Patients’ clinical data were analyzed. Results: Fifteen patients were identified. The median age at diagnosis was 25 years (range: 18–56). Tumors were supratentorial in 47%. Gross-total and near-total resections were achieved in 40%, and sub-total resection in 47%. One (7%) recurrence and no mortality were encountered during a median follow-up of 11 months (range: 1–76). Conclusion: Pilocytic astrocytoma behaves differently in adults compared with pediatrics. It tends to arise in surgically challenging areas where the extent of resection may be limited. Total resection should be the main therapy whenever feasible. The survival rates are good, and recurrence is low.

Plain language summary: Pilocytic astrocytoma is a benign brain tumor that most commonly arises in children. Rarely, this tumor may also arise in adults. Surgical removal of the tumor is the main treatment. In children, the tumor most commonly arises in the cerebellum, a part of the brain where surgical accessibility is good, and complete removal of the tumor significantly decreases the possibility of it recurring. In adults, the tumor is more likely to arise in critical areas of the brain or in areas of limited surgical accessibility, thus, making surgery especially challenging, and preventing complete removal. Moreover, studies found that the probability of the tumor recurring in adults is higher than in children. Studies discussing the properties of pilocytic astrocytoma in adults reported varying results. This is mainly due to the small number of patients studied. The rarity of this tumor makes it hard for large primary studies to be conducted. In this article, we report the characteristics and outcomes of 15 adult patients treated in a single center in Jordan. In our patients, the mean age was 25 years (range: 18–56), and the tumor was located above the tentorium in 47%. Complete and near-complete removal was possible in 40%. The mean duration of follow-up after surgery was 11 months (range: 1–76). The tumor recurred in only one patient. We aim to provide more data on this rare disease and contribute further to understanding its properties.

First draft submitted: 16 August 2021; Accepted for publication: 8 February 2022; Published online: 6 April 2022

Keywords: adult pilocytic astrocytoma ● APA ● grade I glioma ● low-grade glioma ● PCA ● pilocytic astrocytoma

Pilocytic astrocytoma (PCA) is a grade I glioma according to 2016 WHO classification of brain tumors [1]. This benign brain tumor more commonly occurs in children and adolescents accounting for up to 25% of all pediatric brain tumors [2]. The incidence of PCA decreases with age; accounting for less than 2% of gliomas in adults [3]. Surgical resection of the tumor with the goal of complete removal is the main therapy in both pediatrics and adults. The prognosis in pediatrics is very good [4]. However, in adults, the tumor has different characteristics making it more aggressive [5]. Adult pilocytic astrocytoma (APA) is more likely to arise in critical locations where the extent
of resection is limited, making complete resection more challenging [6–8]. In addition, multiple studies reported higher recurrence of the tumor in adults compared with pediatrics [9,10]. These features worsen the prognosis in adults. There have been varying reports on the tumor’s features, prognosis and optimum management, mainly due to the small number of patients.

In this case series, we present the clinical characteristics of 15 patients, greater than 18 years of age, with pathology-proven PCA treated in a single institution in Jordan.

Methods
Institutional Review Board approved retrospective study done at a tertiary cancer center. We searched our database for patients older than 18 years with pathology-proven PCA. Patients with a spinal tumor, age less than 18 years old at the time of diagnosis or recurrence were excluded. Clinical data including age at diagnosis, gender, presenting symptoms, performance status score (WHO score) before and after the operation, and follow-up were analyzed. Additionally, surgical and radiological reports were analyzed to determine the degrees of resection and recurrence. Gross-total resection (GTR) was considered as no residual tumor apparent on postoperative MRI. Near-total resection (NTR) was defined as a thin amount of residual tumor less than 3 mm remaining on postoperative MRI. Sub-total resection (STR) was defined as residual tumor more than 3 mm lining the resection cavity on postoperative MRI.

Furthermore, a literature review was conducted by searching PubMed using the terms ‘pilocytic astrocytoma’[Title/Abstract] AND ‘adult*’[Title/Abstract]) for studies discussing PCA in adults since 2016. Five studies, excluding case reports, that reported the degrees of resection, follow-up and recurrence were chosen, and their results were summarized in Table 3.

Results
A total of fifteen adult pilocytic astrocytoma patients are included in our study. Patients were diagnosed with pilocytic astrocytoma in the period from 2006 to 2020. The patient’s demographic, clinical and pathological characteristics are summarized in Tables 1 and 2. The median age at diagnosis was 25 years (range: 18–56). Males comprised 60% of the study subjects.

Tumor location differed among patients, including one left frontal (6.7%), one left temporal (6.7%), two insular (13.3%), one thalamic (6.7%), two suprasellar (13.3%), five cerebellar (33%), two brain stem (13%) and one in fourth ventricular (6.7%). Seven patients had left-sided tumors, two patients had right-sided tumors, and two patients had a midline tumor. Eight patients (53%) had infratentorial tumors, while seven patients (47%) had supratentorial tumors. One patient has neurofibromatosis.

GTR and NTR were achieved in six patients (40%), STR in seven patients (47%), and biopsy in one patient. Of the eight infratentorial tumors, GTR and NTR were achieved in three (37.5%), STR in three (37.5%), and one (12.5%) biopsy. In the seven supratentorial tumors, three (43%) had NTR, and four (57%) had STRs.

The performance status score before the operation was 0 in five patients, 1 in four patients, 2 in one patient, and 3 in two patients. After the operation, it was 0 in seven patients, 1 in one patient, 2 in one patient, and 3 in two patients. Most patients were only observed postoperatively. One patient received adjuvant chemotherapy following STR of a suprasellar tumor. Two patients were administered adjuvant radiotherapy; one after STR of a posterior fossa tumor, and the other after STR of a suprasellar tumor. One patient received adjuvant chemo-radiotherapy after a biopsy for a cerebellar tumor. Two patients required resurgery; one after partial tumor resection in another center 5 months previously, and one for recurrence of the tumor 3 years after primary surgery (partial resection) in another center.

The follow-up period ranged between 1 and 76 months (median of 11 months). Only one patient (7%) presented with recurrence 3 years after the primary surgery (partial resection). No deaths were reported during the follow-up period.
Table 1. Data of each included subject.

| No. | Age at diagnosis | Gender | Location       | Laterality | Extent of resection | Preoperative performance status | Postoperative performance status | Cystic component | Resurgery | Chemotherapy | Radiotherapy | Tumor recurrence | Follow-up (months) | Neurofibromatosis | Vital status at last follow-up |
|-----|------------------|--------|----------------|------------|---------------------|--------------------------------|---------------------------------|------------------|------------|--------------|--------------|------------------|--------------------|----------------|---------------------------------|
| 1   | 18               | Male   | Cerebellar     | Left       | Biopsy              | 2                              | –                               | Yes              | –          | Yes          | Yes          | No                | 30                 | No             | Alive                           |
| 2   | 18               | Male   | Insular        | Left       | Near-total          | 0                              | 0                               | Yes              | No         | No          | No           | No                | 2                  | No             | Alive                           |
| 3   | 20               | Male   | Suprasellar    | Midline    | Near-total          | 0                              | 0                               | Yes              | No         | Yes          | No           | No                | 23                 | No             | Alive                           |
| 4   | 21               | Male   | Cerebellar     | –          | Sub-total           | –                              | –                               | –                | –          | –            | –            | Yes               | –                  | –              | Alive                           |
| 5   | 22               | Female | 4th ventricle  | –          | Sub-total           | 0                              | 0                               | –                | No         | No          | No           | No                | 1                  | No             | Alive                           |
| 6   | 23               | Male   | Temporal       | Left       | Sub-total           | 1                              | 1                               | Yes              | Yes        | No          | No           | No                | 76                 | No             | Alive                           |
| 7   | 23               | Male   | Insular        | Left       | Near-total          | 3                              | 3                               | Yes              | No         | No          | No           | No                | 7                  | No             | Alive                           |
| 8   | 25               | Female | Suprasellar    | Right      | Sub-total           | –                              | –                               | Yes              | No         | No          | Yes          | –                | –                  | –              | –                               |
| 9   | 28               | Female | Brain stem     | Left       | Sub-total           | 1                              | 3                               | Yes              | No         | No          | No           | No                | 11                 | No             | Alive                           |
| 10  | 31               | Male   | Frontal        | Left       | Sub-total           | 0                              | 0                               | Yes              | No         | No          | No           | No                | 28                 | No             | Alive                           |
| 11  | 38               | Female | Cerebellar     | Left       | Total               | 1                              | 0                               | Yes              | No         | No          | No           | No                | 53                 | Yes            | Alive                           |
| 12  | 43               | Female | Thalamic       | Right      | Sub-total           | 1                              | 0                               | Yes              | No         | No          | No           | No                | 72                 | No             | Alive                           |
| 13  | 44               | Female | Brain stem     | Midline    | Sub-total           | 3                              | 2                               | Yes              | No         | No          | No           | No                | 11                 | No             | Alive                           |
| 14  | 53               | Male   | Cerebellar     | –          | Near-total          | 0                              | 0                               | No               | Yes        | No          | No           | Yes               | 3                  | No             | Alive                           |
| 15  | 56               | Male   | Cerebellar     | –          | Total               | –                              | –                               | –                | –          | –            | –            | No                | 13                 | –              | Alive                           |
Table 2. Descriptive statistics of included patients.

| Variables                               | Pilocytic astrocytoma patients (n = 15) |
|-----------------------------------------|----------------------------------------|
| **Age at diagnosis (median)**           | 25 (range: 18–56)                      |
| **Gender**                              |                                        |
| – Male                                  | 9 (60%)                                |
| – Female                                | 6 (40%)                                |
| **Location**                            |                                        |
| – Frontal                               | 1 (6.7%)                               |
| – Temporal                              | 1 (6.7%)                               |
| – Insular                               | 2 (13.3%)                              |
| – Thalamic                              | 1 (6.7%)                               |
| – Suprasellar                           | 2 (13.3%)                              |
| – Cerebellar                            | 5 (33%)                                |
| – Brain stem                            | 2 (13%)                                |
| – 4th ventricle                         | 1 (6.7%)                               |
| – Supratentorial                        | 7 (47%)                                |
| – Infratentorial                        | 8 (53%)                                |
| **Laterality**                          |                                        |
| – Right                                 | 2 (13.3%)                              |
| – Left                                  | 7 (46.7%)                              |
| – Midline                               | 2 (13%)                                |
| **Extent of resection**                 |                                        |
| – Biopsy                                | 1 (6.7%)                               |
| – Sub-total                             | 7 (47%)                                |
| – Near-total                            | 4 (27%)                                |
| – Total                                 | 2 (13.3%)                              |
| **Preoperative performance status**     |                                        |
| – 0                                     | 5 (33.3%)                              |
| – 1                                     | 4 (26.7%)                              |
| – 2                                     | 1 (6.7%)                               |
| – 3                                     | 2 (13.3%)                              |
| **Postoperative performance status**    |                                        |
| – 0                                     | 7 (46.7%)                              |
| – 1                                     | 1 (6.7%)                               |
| – 2                                     | 1 (6.7%)                               |
| – 3                                     | 2 (13.3%)                              |
| **Cystic component**                   |                                        |
| – Yes                                   | 11 (73.3%)                             |
| – No                                    | 1 (6.7%)                               |
| **Resurgery**                           |                                        |
| – Yes                                   | 2 (13.3%)                              |
| – No                                    | 10 (67%)                               |
| **Chemotherapy**                        |                                        |
| – Yes                                   | 2 (13.3%)                              |
| – No                                    | 11 (73.3%)                             |
| **Radiotherapy**                        |                                        |
| – Yes                                   | 3 (20%)                                |
| – No                                    | 11 (73%)                               |
| **Tumor recurrence or progression (during follow-up)** |                       |
| – Yes                                   | 1 (7%)                                 |
| – No                                    | 13 (87%)                               |

Data are presented as numbers (percentage) or mean (standard deviation).
Table 2. Descriptive statistics of included patients (cont.).

| Variables                      | Pilocytic astrocytoma patients (n = 15) |
|--------------------------------|----------------------------------------|
| Neurofibromatosis              |                                        |
| – Yes                          | 1 (6.7%)                               |
| – No                           | 11 (73%)                               |
| Follow-up (months)             | Median: 12 (1–76)                      |
| Vital status at last follow-up|                                        |
| – Alive                        | 14 (93%)                               |
| – Dead                         | 0                                      |

Data are presented as numbers (percentage) or mean (standard deviation).

Discussion
PCA is a WHO grade I glioma. 2016 WHO classification of tumors of the CNS described them as borderline benign/malignant entities with uncertain behavior patterns [1]. PCA comprises 5% of all gliomas [11]. They are well-circumscribed, cystic, slowly growing tumors derived from neuroepithelial tissue [12]. Histologically, they are characterized by a biphasic pattern with varying proportions of compacted bipolar cells with Rosenthal fibers and loose textured multipolar cells with microcysts and granular bodies [13].

A review by Gregory et al. on the molecular aspects of PCA reported that MAPK is the most common molecular alteration in PCA. KIAA1549-BRAF fusion (BK fusions) are the most common driver mutations of MAPK but their prevalence decreases with age [14]; BK fusions have been associated with improved progression-free survival and an overall better prognosis in pediatrics [15,16]. Theeler et al. found BK fusions in 20% of APA patients. However, it was found that BK fusions do not influence outcomes in adults [14,17]. Other notable MAPK-activating mutations include BRAF mutations (BRAFV600E) found in 9.2% of APA patients and mutations in tyrosine kinase FGFR1 found in 7–14% of APA patients [15,18,19].

PCA most commonly arises in the pediatric age group, comprising approximately 25% of pediatric brain tumors. The incidence of PCA decreases with age, comprising only 1.5% of adult brain tumors [3,4,20–22]. In a study done by Theeler et al., only three (2.4%) out of 127 adult PCA cases were older than 60 years [6]. The median age in our group was 25 years (range: 18–56), including two patients older than 50 years.

PCA more frequently arises in the cerebellum and supratentorial structures. Maharaj et al. studied 28 pediatric patients with PCA; Tumor locations were cerebellar in 64%, hypothalamic in 18%, thalamic in 11%, corpus callosal in 4%, and the fourth ventricle in 4% [23]. Mair et al. studied 46 adult patients with PCA; 58.8% were supratentorial. Among the supratentorial lesions, 17.4% were in the optic nerve with hypothalamic involvement, 17.4% in the optic nerve without hypothalamic involvement, and 17.4% in the cerebral hemispheres. Infratentorial lesions were observed in 41.2% of patients; 17.6% were in the cerebellar hemispheres, 14.7% were cerebellar lesions with involvement of the brainstem, and 8.8% were lower brainstem/spinal lesions [10]. Johnson et al. and Theeler et al. reported that PCA in adults is more commonly supratentorial [6,24]. In contrast, Jungk et al. found equal tumor distribution among the supratentorial and infratentorial compartments (47 vs 53%) [25]. In our cohort, 47% of the tumors were supratentorial.

In both pediatrics and adults, the ideal treatment for PCA is GTR [7,26]. The degree of resection is affected by the location of the tumor. Tumors in eloquent and deeper areas of the brain such as the brainstem, diencephalon, insula, optic nerve and hypothalamus, for example, are harder to completely resect compared with tumors in the cerebellum or the cerebral convexity [18,23]. In our cohort, 53.3% of tumors were in critical areas where the extent of resection was limited, preventing complete resection. Jungk et al. found that GTR is more achievable in infratentorial than supratentorial tumors [25]. Johnson et al. reported GTR in 40% of tumors in adults and 45% of tumors in pediatrics [24]. Ryu et al. reported GTR in 55% of adults and 58% of pediatricians. More recent studies on adults reported GTR achievement ranging between 39 and 67% of their patients (Table 3) [7,10,25,27,28]. In our cohort, 40% of patients.

GTR was associated with greater than 95% 10-year survival in pediatrics [4,26,29]. In a study by Saunders et al., the rate of recurrence after GTR in pediatrics was 10% [30]. Thus, PCA in pediatrics is regarded to have an excellent prognosis. However, in adults, the prognosis after surgery is not as good as in pediatrics [5,11,31–33]. Multiple studies on adults reported varying rates of recurrence ranging from 13 to 40%. The rate of recurrence after treatment varied depending on the type of treatment and the degree of resection (Table 3 summarizes the results of five
### Table 3. A summary of the results of similar studies.

| Study (year) | Number of patients | Age | Extent of resection | Adjuvant therapy | Recurrence | Follow-up | Survival | Ref. |
|--------------|-------------------|-----|---------------------|------------------|------------|-----------|----------|------|
| Mair et al. (2020) | 46 patients | Median age: 32.5 years (19–75) | GTR: 56.3% | Not administered | 19.60% | Median 53.0 months (0.5–300.1) | 5-year OS: 85.3% | 10 |
| Nelson et al. (2019) | 50 patients | Median age: 29 years (16–76) | GTR: 44% | After GTR: none | 40% | Whole group: median 3.5 years (0–21) | 5-year OS: 80% | 27 |
| Jungk et al. (2019) | 58 patients | Median age: 30 years (17–66) | GTR: 67% | Chemotherapy (TMZ): 2% | 28% | Median 72 months (3–259) | 5-year PFS: 67% | 25 |
| Boschetti et al. (2020) | 23 patients | Median age: 26 years (18–51) | GTR: 39% | Radiotherapy: one patient after GTR | 19% | Median 88.9 months (1.9–330.4) | – | 28 |
| Bond et al. (2018), institutional series | 46 patients | Mean age: 33.6 ±13.3 years (range 18–76) | GTR: 52% | Chemotherapy: one patient after biopsy | 13% | Median 73 months (1–204) | 95% alive at last follow-up | 7 |
| Bond et al. (2018), meta-analysis | 254 | – | GTR: 51% | – | 31% | Weighted mean follow-up of 77.7 ±49.6 months (31–250) | OS: 85% alive at last follow-up | 7 |

GTR: Gross-total resection; NTR: Near-total resection; OS: Overall survival; PFS: Progression-free survival; STR: Sub-total resection; TMZ: Temozolomide.

Recent studies). In a meta-analysis by Bond et al., 254 adult patients who had undergone GTR were followed for an average of 77 months had a 28% rate of recurrence [7]. In a study by Jungk et al. on 58 patients, the rate of recurrence was 10% after complete resection, and 63% in patients who had incomplete resection or biopsy [25]. Mair et al. reported 4% recurrence with complete resection and 38.9% with incomplete resection [10]. In a Brazilian study including 23 patients, the rate of recurrence was the same after GTR and STR (9%). Interestingly, a study by Parsons et al. including 3380 adult patients found no difference in overall survival after GTR or STR [34]. In our group, two patients were reoperated on in our center after being treated elsewhere: one after partial resection 5 months prior, and the other for recurrence 3 years after partial resection.

While some studies on adult patients reported high recurrence rates and mortality, other studies described favorable prognosis and recurrence but still not as favorable as in pediatrics [32,35–38]. A recent meta-analysis of seven case series including 254 patients confirmed that GTR is a positive prognostic factor in adult PCA just like in pediatric PCA. However, the same study also reported a mean recurrence rate as high as 31% in adult PCA [7].

Further discussion arises on how patients with incompletely resected tumors should be further managed; whether by observation, radiotherapy and/or chemotherapy [34,39,40]. Here again has different studies yielded varying results [6,18,32,38,40,41]. Targeted therapy against MAPK pathway is a developing area of research expected to play a major role in the treatment of gliomas. A review by Gregory et al. discussed the advancements in targeted therapy against MAPK pathway as a treatment for APA [18].

10.2217/cns-2021-0014 CNS Oncol. (2022) CNS81 future science group
Despite the variations in the characteristics of APA between different studies, the tendency of APA to arise in surgically challenging locations and its higher recurrence rates suggest that PCA in adults is more aggressive than in pediatrics. Further studies with a larger number of patients are required to better understand the nature of the tumor in adults. However, the rarity of adult PCA makes this difficult.

The limitations of our study are the retrospective nature of data collection, the small number of patients and patients being lost to follow-up.

**Conclusion**

In this case series, we presented 15 patients, greater than 18 years of age, with pathology-proven PCA treated in a single institution in Jordan. In the literature, APA is reported to behave more aggressively, with higher recurrence rates, when compared with PCA in pediatrics. In our group, tumor location was infratentorial in 53% of patients. Thirty-three percent of the tumors were cerebellar. 53.3% arose in eloquent or deeper locations where surgical respectability was restricted. Forty-seven percent of tumors were subtotally resected. Total resection and near-total could only be achieved in 40% of tumors. Only one patient suffered a recurrence. No patients died during follow-up. We aim to provide more data on this rare disease and contribute further to understanding its prognostic properties.

**Summary points**

- Pilocytic astrocytoma (PCA) is a tumor that most commonly occurs in pediatrics with an excellent prognosis after surgical resection.
- The incidence of PCA decreases with age, comprising less than 2% of adult brain tumors. The rarity of PCA in adults has made it hard for large primary studies to be conducted.
- Pediatric PCA is more commonly infratentorial than supratentorial with the majority being cerebellar.
- Adult pilocytic astrocytoma is more likely to arise in supratentorial locations and in areas that are more surgically challenging, such as suprasellar or insular, than in pediatrics. Therefore, achieving gross-total resection in adults is more challenging.
- Surgical treatment with the aim of total resection of the tumor is the main therapy. Recurrence rates are inversely related to the degree of resection.
- The need for adjuvant chemo or radiotherapy is still debatable in adult pilocytic astrocytoma.
- Multiple studies have reported increased rates of recurrence of the tumor in adults compared with pediatrics.
- The propensity to arise in sensitive locations and the higher rate of recurrence indicate that PCA is more aggressive in adults.

**Author contributions**

BA Muhsen contributed to the conception and design of the work, data collection, analysis and interpretation, in addition to revising and final approval of the manuscript. Al Aljariri contributed to the design of the work, drafting, writing and reviewing the manuscript. M Elayyan contributed to acquisition of the data and reviewing the manuscript. H Hirbawi contributed to writing and reviewing the manuscript. MA Masri contributed to acquisition of the data and reviewing the manuscript.

**Financial & competing interests disclosure**

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

**Ethical conduct of research**

Written informed consent was obtained from the patients for publication of this paper.

**Open access**

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
References

Papers of special note have been highlighted as: ● of interest; ●● of considerable interest

1. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131(6), 803–820 (2016).

2. Ryu H, Jung T, Lee G, Lee K. Differences in the clinical courses of pediatric and adult pilocytic astrocytomas with progression: a single-institution study. Childs Nerv. Syst. 31(11), 2063–2069 (2015).

3. Ostrom QT, Gittleman H, Fulop J et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neurol. Oncol. 17(Suppl. 4), iv1–iv62 (2015).

4. Burkhard C, Di Patre P-L, Schuler D. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuprol. Appl. Neurobiol. 37(7), 803–806 (2011).

5. Bond KM, Hughes JD, Porter AL, Orina J, Fang S, Parney IF. Adult pilocytic astrocytoma: an institutional series and systematic literature review for extent of resection and recurrence. World Neurosurg. 110, 276–283 (2018).

6. Mair MJ, Wohrer A, Furtner J et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. J. Neurooncol. 114(2), 97–109 (2007).

7. Collins VP, Jones DTW, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 129(6), 775–788 (2015).

8. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97–109 (2007).

9. Brugger PC, Scheithauer BW, Stephen VF. Surgical pathology of the nervous system and its coverings. Proc. R. Soc. Med. 70(5), 360–361 (1977).

10. Hasselblatt M, Riesmeier B, Lechataye B et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuprol. Appl. Neurobiol. 37(7), 803–806 (2011).

11. Becker AP, Scapulatempo-Neto C, Carloni AC et al. BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. J. Neurooncol. Exp. Neurol. 74(7), 743–754 (2015).

12. Hawkins C, Walker E, Mohamed N et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin. Cancer Res. 17(14), 4790–4798 (2011).

13. Bond KM, Hughes JD, Porter AL, Orina J, Fang S, Parney IF. Adult pilocytic astrocytoma: an institutional series and systematic literature review for extent of resection and recurrence. World Neurosurg. 110, 276–283 (2018).

14. Tahler BJ, Ellezam B, Sadighi ZS et al. Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuropathol. Appl. Neurobiol. 70(5), 360–361 (2019).

15. Barselomo C, Albright I, Kriegel C et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. J. Neurooncol. 114(2), 97–109 (2007).

16. Gregory TA. Adult pilocytic astrocytoma in the molecular era: a comprehensive review. CNS Oncol. 10(1), CNS68 (2021).

17. Trisolini E, EI D, Marine W et al. Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas. J. Neurooncol. 145(2), 241–245 (2019).

18. Pollack IF, Claassen D, Al-Shboul Q, Janosky JE, Deutsch M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J. Neurosurg. 82(4), 536–547 (1995).

19. Schneider JH Jr, Raffel C, McComb JG. Benign cerebellar astrocytomas of childhood. Neursurg.ry 30(1), 58–62 (1992).

20. Laws ER, Taylor W, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg. 61(4), 665–673 (1984).

21. Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J. Neurooncol. 108(1), 187–193 (2012).

22. Bond KM, Hughes JD, Porter AL, Orina J, Fang S, Parney IF. Adult pilocytic astrocytoma: an institutional series and systematic literature review for extent of resection and recurrence. World Neurosurg. 110, 276–283 (2018).

23. Maurer A, Manoranjan B, Verhey LH. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. J. Neurooncol. 114(2), 97–109 (2007).

24. Hawkins C, Walker E, Mohamed N et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin. Cancer Res. 17(14), 4790–4798 (2011).
25. Jungk C, Reinhardt A, Wara B et al. Extent of resection, MGMT promoter methylation status and tumor location independently predict progression-free survival in adult sporadic pilocytic astrocytoma. *Cancers (Basel)* 11(8), 1–15 (2019).

- Recent study that identified MGMT promoter methylation and tumor location as prognostic properties.

26. Khalafallah AM, Jimenez AE, Shah PP, Brem H, Mukherjee D. Effect of radiation therapy on overall survival following subtotal resection of adult pilocytic astrocytoma. *J. Clin. Neurol.* 81, 340–345 (2020).

27. Nelson AJ, Zakaria R, Jenkinson MD, Andrew R, Nelson AJ. Extent of resection predicts risk of progression in adult pilocytic astrocytoma. *Br. J. Neurosurg.* 33(3), 343–347 (2019).

- Recent study that reported the clinical characteristics and outcomes of 50 APA patients.

28. Boschetti G, Santos AJ, Fermon KP et al. Adult pilocytic astrocytomas: a Brazilian series. *World Neurosurg.* 133, e115–e120 (2020).

29. Georgakis MK, Karalexi MA, Kalogiour EL et al. Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US. *J. Neurooncol.* 131(1), 163–175 (2017).

30. Saunders DE, Phipps KP, Wade AM, Hayward RD. Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma. *J. Neurosurg.* 102(Suppl. 2), 172–178 (2005).

31. Kano H, Konstdzialka D, Nitizan A, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for pilocytic astrocytomas part 1: outcomes in adult patients. *J. Neurooncol.* 95(2), 211–218 (2009).

32. Johnson DR, Brown PD, Galanis E, Hambuck JE. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. *J. Neurooncol.* 108(1), 187–193 (2012).

33. Stüer C, Vilt B, Majores M, Becker A, Schramm J, Simon M. Frequent recurrence and progression in pilocytic astrocytoma in adults. *Cancer* 110(12), 2799–2808 (2007).

34. Parsons MW, Whipple NS, Poppe MM, Mender JS, Cannon DM, Burt LM. The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. *J. Neurooncol.* 151(2), 93–101 (2021).

35. Stüer C, Vilt B, Majores M, Becker A, Schramm J, Simon M. Frequent recurrence and progression in pilocytic astrocytoma in adults. *Cancer* 110(12), 2799–2808 (2007).

36. Lee KJ, Marchan E, Peterson J et al. Management and survival of adult patients with pilocytic astrocytoma in the National Cancer Database. *World Neurosurg.* 112, e881–e887 (2018).

- This included a large cohort of APA patients after reviewing the national cancer database. The authors provided prognostic information of APA.

37. Bell D, Chitnavis BP, Al-Sarraj S, Connor S, Sharr MM, Gullan RW. Pilocytic astrocytoma of the adult – clinical features, radiological features and management. *Br. J. Neurol.* 18(6), 613–616 (2004).

38. Brown PD, Anderson SK, Carrero XW et al. Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance). *Neurooncol. Pract.* 2, 199–204 (2015).

39. World Health Organization. Fritz A, Percy C, Jack A et al. (Eds). *International Classification of Diseases for Oncology (3rd Edition).* (2013). https://apps.who.int/iris/handle/10665/42344

40. Ishkanian A, Laperriere NJ, Xu W, Millar B. Upfront observation versus radiation for adult pilocytic astrocytoma. *Cancer* 117(17), 4070–4079 (2011).

41. Khalafallah AM, Jimenez AE, Shah PP, Brem H, Mukherjee D. Effect of radiation therapy on overall survival following subtotal resection of adult pilocytic astrocytoma. *J. Clin. Neurol.* 81, 340–345 (2020).

- Large study that assessed the effectiveness of postoperative radiotherapy after sub-total resection.